Combined prostacyclin and thromboxane synthetase inhibitor UK 38485 in flap survival.
Thromboxane, a prostanoid derivative, is a central mediator of the progressive dermal ischemia seen in the distal dying flap. Prostacyclin; a vasoactive prostanoid derivative, has been found to enhance ischemic flap survival. This study examines the effects of prostacyclin and UK 38485 (specific thromboxane synthetase inhibitor), separately and combined, in axial flap survival in the pig. Each increased flap survival over control flaps; their combined use demonstrated an even greater flap survival (p less than 0.005).
Zachary
L S
LS
Division of Plastic and Reconstructive Surgery, Wayne State University School of Medicine, Detroit, MI 48201.
Heggers
J P
JP
Robson
M C
MC
Murphy
R C
RC
D000818:Animals; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage*; D006085:Graft Survival / Q000187:drug effects*; D007093:Imidazoles / Q000008:administration & dosage*; D007261:Infusions, Intra-Arterial; D013524:Surgical Flaps; D013552:Swine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; C039242:dazmegrel; D011464:Epoprostenol; D013930:Thromboxane-A Synthase